Terms: = Breast cancer AND CBFB, PEBP2B, 865, ENSG00000067955, Q13951 AND Prognosis
27 results:
1. [Identification of breast cancer subtypes based on graph convolutional network].
An Y; Liu X; Chen H; Wan G
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2024 Feb; 41(1):121-128. PubMed ID: 38403612
[TBL] [Abstract] [Full Text] [Related]
2. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract] [Full Text] [Related]
3. Significance of Tumor-Stroma Ratio (TSR) in Predicting Outcomes of Malignant Tumors.
Pyo JS; Kim NY; Min KW; Kang DW
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512068
[No Abstract] [Full Text] [Related]
4. The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in breast cancer Patients.
Hameed BH; Abdulsatar Al-Rayahi I; Muhsin SS
Arch Razi Inst; 2022 Oct; 77(5):1873-1879. PubMed ID: 37123148
[TBL] [Abstract] [Full Text] [Related]
5. cancer-Associated Exosomal cbfb Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of breast cancer Progression.
Hsu CH; Ma HP; Ong JR; Hsieh MS; Yadav VK; Yeh CT; Chao TY; Lee WH; Huang WC; Kuo KT; Fong IH; Lin CC; Su CM
Dis Markers; 2022; 2022():8446629. PubMed ID: 35903297
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in breast cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract] [Full Text] [Related]
7. A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.
Gong C; Cheng Z; Yang Y; Shen J; Zhu Y; Ling L; Lin W; Yu Z; Li Z; Tan W; Zheng C; Zheng W; Zhong J; Zhang X; Zeng Y; Liu Q; Huang RS; Komorowski AL; Yang ES; Bertucci F; Ricci F; Orlandi A; Franceschini G; Takabe K; Klimberg S; Ishii N; Toss A; Tan MP; Cherian MA; Song E
Sci China Life Sci; 2022 Nov; 65(11):2205-2217. PubMed ID: 35579777
[TBL] [Abstract] [Full Text] [Related]
8. Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients.
Xi G; Guo W; Kang D; Ma J; Fu F; Qiu L; Zheng L; He J; Fang N; Chen J; Li J; Zhuo S; Liao X; Tu H; Li L; Zhang Q; Wang C; Boppart SA; Chen J
Theranostics; 2021; 11(7):3229-3243. PubMed ID: 33537084
[TBL] [Abstract] [Full Text] [Related]
9. The transcription factor cbfb mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract] [Full Text] [Related]
10. Development of a prediction model for breast cancer based on the national cancer registry in Taiwan.
Huang CC; Chan SY; Lee WC; Chiang CJ; Lu TP; Cheng SH
Breast Cancer Res; 2019 Aug; 21(1):92. PubMed ID: 31409418
[TBL] [Abstract] [Full Text] [Related]
11. Education Level Is a Strong Prognosticator in the Subgroup Aged More Than 50 Years Regardless of the Molecular Subtype of breast cancer: A Study Based on the Nationwide Korean breast cancer Registry Database.
Hwang KT; Noh W; Cho SH; Yu J; Park MH; Jeong J; Lee HJ; Kim J; Oh S; Kim YA;
Cancer Res Treat; 2017 Oct; 49(4):1114-1126. PubMed ID: 28161933
[TBL] [Abstract] [Full Text] [Related]
12. Do Patients with Luminal A breast cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Diessner J; Wischnewsky M; Blettner M; Häusler S; Janni W; Kreienberg R; Stein R; Stüber T; Schwentner L; Bartmann C; Wöckel A
PLoS One; 2016; 11(12):e0168730. PubMed ID: 27992550
[TBL] [Abstract] [Full Text] [Related]
13. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less.
Toss A; Palazzo J; Berger A; Guiles F; Sendecki JA; Simone N; Anne R; Avery T; Jaslow R; Lazar M; Tsangaris T; Cristofanilli M
Breast; 2016 Oct; 29():223-30. PubMed ID: 27506636
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Role of Programmed Death Ligand-1 Expression in breast cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract] [Full Text] [Related]
15. Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer.
Wang CA; Liu Q; Chen Y; Liu S; Xu J; Cui X; Zhang Y; Piao L
Exp Mol Pathol; 2015 Apr; 98(2):254-9. PubMed ID: 25617527
[TBL] [Abstract] [Full Text] [Related]
16. Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor.
Shargh SA; Sakizli M; Khalaj V; Movafagh A; Yazdi H; Hagigatjou E; Sayad A; Mansouri N; Mortazavi-Tabatabaei SA; Khorram Khorshid HR
Med Oncol; 2014 Nov; 31(11):250. PubMed ID: 25260805
[TBL] [Abstract] [Full Text] [Related]
17. Subcellular localization of Mdm2 expression and prognosis of breast cancer.
Park HS; Park JM; Park S; Cho J; Kim SI; Park BW
Int J Clin Oncol; 2014 Oct; 19(5):842-51. PubMed ID: 24292333
[TBL] [Abstract] [Full Text] [Related]
18. prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
Amant F; von Minckwitz G; Han SN; Bontenbal M; Ring AE; Giermek J; Wildiers H; Fehm T; Linn SC; Schlehe B; Neven P; Westenend PJ; Müller V; Van Calsteren K; Rack B; Nekljudova V; Harbeck N; Untch M; Witteveen PO; Schwedler K; Thomssen C; Van Calster B; Loibl S
J Clin Oncol; 2013 Jul; 31(20):2532-9. PubMed ID: 23610117
[TBL] [Abstract] [Full Text] [Related]
19. Sequence analysis of mutations and translocations across breast cancer subtypes.
Banerji S; Cibulskis K; Rangel-Escareno C; Brown KK; Carter SL; Frederick AM; Lawrence MS; Sivachenko AY; Sougnez C; Zou L; Cortes ML; Fernandez-Lopez JC; Peng S; Ardlie KG; Auclair D; Bautista-Piña V; Duke F; Francis J; Jung J; Maffuz-Aziz A; Onofrio RC; Parkin M; Pho NH; Quintanar-Jurado V; Ramos AH; Rebollar-Vega R; Rodriguez-Cuevas S; Romero-Cordoba SL; Schumacher SE; Stransky N; Thompson KM; Uribe-Figueroa L; Baselga J; Beroukhim R; Polyak K; Sgroi DC; Richardson AL; Jimenez-Sanchez G; Lander ES; Gabriel SB; Garraway LA; Golub TR; Melendez-Zajgla J; Toker A; Getz G; Hidalgo-Miranda A; Meyerson M
Nature; 2012 Jun; 486(7403):405-9. PubMed ID: 22722202
[TBL] [Abstract] [Full Text] [Related]
20. Public awareness of colorectal cancer and screening in a Spanish population.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Jiménez-Sosa A
Public Health; 2011 Sep; 125(9):609-15. PubMed ID: 21794885
[TBL] [Abstract] [Full Text] [Related]
[Next]
